Loading…
Maintaining American Superiority by Improving Export Control Transparency Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
94pct
187d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
Maintaining American Superiority by Improving Export Control Transparency Act This act requires the Department of Commerce's Bureau of Industry and Security (BIS) to annually report to Congress on export control licensing. Under current law, BIS administers and enforces controls on the export of dual-use goods (e.g., items with both civilian and military uses) and certain military parts and components. These export controls are implemented primarily under the Export Control Reform Act of 2018 (ECRA) through the Export Administration Regulations (EAR). Under this act, BIS must annually report to Congress on license applications, other requests for authorization, and end-use checks (on-site verifications conducted by BIS) for the export, reexport, release, and in-country transfer of items subject to the EAR to covered entities. A covered entity is any entity that (1) is located in a country listed in Country Group D:5 (countries that are identified by the Department of State as subject to U.S. arms embargoes), and (2) is included on the Entity List or the Military End-User List (two of the lists published by BIS containing information on the individuals, organizations, and addresses subject to restrictions involving items subject to the EAR). The act requires this report to include specified information, such as the name of the entity submitting the application, where the item is being exported, the decision with respect to the license application or authorization, and information on any end-use checks to ensure compliance with U.S. export controls. The information shall be exempt from public disclosure (except for aggregate statistics). Additionally, BIS must exclude from the report any information that could jeopardize an ongoing investigation.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2026 · third_quarter · Health Issues
Became Public Law No: 119-34.
Became Public Law No: 119-34.
Signed by President.
Signed by President.
Presented to President.
Presented to President.
Message on Senate action sent to the House.
Passed Senate without amendment by Unanimous Consent. (consideration: CR S4573)
Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.
Senate Committee on Banking, Housing, and Urban Affairs discharged by Unanimous Consent.
Senate Committee on Banking, Housing, and Urban Affairs discharged by Unanimous Consent.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Living Donor Protection Act (H.R. 4583 / S. 1552); FY 2027 appropriations funding for nursing workforce development programs and National Institute of Nursing Research; FY 2027 funding kidney disease research at NIDDK at NIH; Funding for AHRQ at HHS in FY 2027; Workplace Violence Prevention for Health Care and Social Service Workers Act (H.R. 2531 / S. 1232); Restore Protections for Dialysis Patients Act (H.R. 2199 / S. 1173); Organ Donation Referral Improvement Act (H.R. 330); The Improving Care & Access to Nurses Act (H.R. 1316 / S. 575); Providing Real-world Education and Clinical Experience by Precepting Tomorrow's Nurses Act (H.R. 392 / S. 131); Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R.929 / S.266); Living Donor FMLA Protection Act (H.R. 4582); Improving Access to Home Dialysis Act; Future Advancement of Academic Nursing Act (H.R. 6607 / S. 3435); Title VIII Reauthorization Act (H.R. 3593 / S. 1874); Kidney Care Protection Act (H.R. 6214 / S. 2730); Nursing is a Professional Degree Act (H.R. 8691 / S. 4568); Share Act (H.R. 2332); Promoting Access to Diabetic Shoes Act (H.R. 1616).
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Living Donor Protection Act (H.R. 4583 / S. 1552); FY 2027 appropriations funding for nursing workforce development programs and National Institute of Nursing Research; FY 2027 funding kidney disease research at NIDDK at NIH; Funding for AHRQ at HHS in FY 2026; Workplace Violence Prevention for Health Care and Social Service Workers Act (H.R. 2531 / S. 1232); Restore Protections for Dialysis Patients Act (H.R. 2199 / S. 1173); Organ Donation Referral Improvement Act (H.R. 330); The Improving Care & Access to Nurses Act (H.R. 1316 / S. 575); Providing Real-world Education and Clinical Experience by Precepting Tomorrow's Nurses Act (H.R. 392 / S. 131); Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R.929 / S.266); Living Donor FMLA Protection Act (H.R. 4582); Improving Access to Home Dialysis Act; Future Advancement of Academic Nursing Act (H.R. 6607 / S. 3435); Title VIII Reauthorization Act (H.R. 3593 / S. 1874); Kidney Care Protection Act (H.R. 6214 / S. 2730); Nursing is a Professional Degree Act (H.R. 8691 / S. 4568).
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Living Donor Protection Act (H.R. 4583 / S. 1552); FY 2027 appropriations funding for nursing workforce development programs and National Institute of Nursing Research; FY 2027 funding kidney disease research at NIDDK at NIH; Funding for AHRQ at HHS in FY 2026; Workplace Violence Prevention for Health Care and Social Service Workers Act (H.R. 2531 / S. 1232); Restore Protections for Dialysis Patients Act (H.R. 2199 / S. 1173); Organ Donation Referral Improvement Act (H.R. 330); The Improving Care & Access to Nurses Act (H.R. 1316 / S. 575); Providing Real-world Education and Clinical Experience by Precepting Tomorrow's Nurses Act (H.R. 392 / S. 131); Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R.929 / S.266); Living Donor FMLA Protection Act (H.R. 4582); Improving Access to Home Dialysis Act; Future Advancement of Academic Nursing Act (H.R. 6607 / S. 3435).
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Trade (domestic/foreign)
General issues related to export controls, including H.R. 1316/S. 744, the Maintaining American Superiority by Improving Export Control Transparency Act, and issues related to tariffs and foreign direct investment in the U.S., License Monopoly prevention and related issues including S.3200 License Monopoly Prevention Act. General issues related to export controls, including H.R.3477/S.1705, the Chip Security Act.
Client expense: $136,980 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
Living Donor Protection Act (H.R. 4583 / S. 1552); FY 2026 appropriations funding for nursing workforce development programs and National Institute of Nursing Research; FY 2026 funding kidney disease research at NIDDK at NIH; Funding for AHRQ at HHS in FY 2026; Workplace Violence Prevention for Health Care and Social Service Workers Act (H.R. 2531 / S. 1232); Restore Protections for Dialysis Patients Act (H.R. 2199 / S. 1173); Organ Donation Referral Improvement Act (H.R. 330); The Improving Care & Access to Nurses Act (H.R. 1316 / S. 575); Providing Real-world Education and Clinical Experience by Precepting Tomorrow's Nurses Act (H.R. 392 / S. 131); Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R.929 / S.266); Living Donor FMLA Protection Act (H.R. 4582); Improving Access to Home Dialysis Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Trade (domestic/foreign)
General issues related to export controls, including H.R. 1316/S. 744, the Maintaining American Superiority by Improving Export Control Transparency Act, and issues related to tariffs and foreign direct investment in the U.S., License Monopoly prevention and related issues. General issues related to export controls, including H.R.3477/S.1705, the Chip Security Act.
Client expense: $136,980 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Banking
H.R. 1316, Maintaining American Superiority by Improving Export Control Transparency Act, all provisions. H.R. 1920, FARMLAND Act of 2025, all provisions. H.R. 2548, Sanctioning Russia Act of 2025, all provisions. H.R. 3190, BRAVE Burma Act, all provisions. H.R. 4346, Preventing the Escalation of Armed Conflict in Europe (PEACE) Act of 2025, all provisions. H.R. 4397, Muslim Brotherhood Terrorist Designation Act of 2025, all provisions. H.R. 4423, No New Burma Funds Act, all provisions. H.R. 4427, Syria Sanctions Accountability Act of 2025, all provisions. H.R. 4830, Uyghur Genocide Accountability and Sanctions Act of 2025, all provisions. H.R. 5495, Strengthening Entry Visa Enforcement and Restrictions (SEVER) Act, all provisions. H.R. 5606, Return to Palestinian Entities Accountability and Counterterrorism Enforcement (Return to PEACE) Act, all provisions. H.R. 747, Stop Chinese Fentanyl Act of 2025, all provisions. S. 1241, Sanctioning Russia Act of 2025, all provisions. S. 1969, AFIDA Improvements Act of 2025, all provisions. S. 2293, Muslim Brotherhood Terrorist Designation Act of 2025, all provisions. S. 2400, Art Market Integrity Act, all provisions. S. 2560, Uyghur Genocide Accountability and Sanctions Act of 2025, all provisions. S. 2893, Strengthening Entry Visa Enforcement and Restrictions (SEVER) Act, all provisions. S. 2904, SHADOW Fleet Sanctions Act of 2025, all provisions. S. 63, CBW Fentanyl Act, all provisions. S. 744, Maintaining American Superiority by Improving Export Control Transparency Act, all provisions. S. 860, Break Up Suspicious Transactions of (BUST) Fentanyl Act, all provisions. S. 886, FARMLAND Act of 2025, all provisions. Issues related to Anti-Money Laundering and Combating the Financing of Terrorism in Art Markets; Captagon, Fentanyl, and International Narcotics Production and Trafficking; China-Related Tax and Investment Authorities; Chinese Access to U.S. Capital Markets and Advanced Technology; Chinese Involvement with Fentanyl Trafficking; Evaluating Sanctions, Export Controls, and AML Regulations, Regulatory Authorities, and Legislative Authorities; Expansion of Trade Transparency Units; Foreign Gift Compliance Transparency; Foreign Influence in U.S. Nonprofit Sector; Foreign Land Purchases Near Sensitive U.S. Sites; Hamas Smuggling Tunnels, Financial Assets, and Funding Streams; Hezbollahs International Financing Network; Iran Funding Streams; Iranian Oil Sanctions Enforcement; National Security-Related Foreign Investment Screening Processes for U.S. Allies; Outbound Investment Transparency; Protecting U.S. Small Businesses from Foreign Influences; Shipping Manifest Transparency; Tax Exemptions for Foreign Sovereign Wealth Funds; Tax-Exempt Status of Terrorist Supporting Organizations; U.S. Anti-Corruption Sanctions and Strategy; U.S. Beneficial Ownership Policy; U.S. Cartels Sanctions Policy; U.S. China Sanctions Policy; U.S. Counter-Narcotics Strategy; U.S. Export Control Policy; U.S. Hezbollah Sanctions Policy; U.S. Houthis Sanctions Policy; U.S. ICC Sanctions Policy; U.S. Iran Sanctions Policy; U.S. Iraq Sanctions Policy; U.S. Muslim Brotherhood Sanctions Policy; U.S. Narcotics Sanctions Policy; U.S. Polisario Front Sanctions Policy; U.S. Russia Sanctions Policy; U.S. Sanctions Authorities, Implementation, Enforcement, Resourcing, and Policy; U.S. SST Designation Reform; U.S. Syria Sanctions Policy; U.S. Terror Finance Policy; U.S. Terrorism Sanctions Policy; and U.S. Turkey Sanctions Policy (no bill).
2025 · third_quarter · Foreign Relations
Urging the administration to robustly enforce the Global Magnitsky Human Rights Accountability Act; Urging the Administration to resume, and appropriate future, U.S. foreign assistance for government accountability or transparency programs; H.R.1316, Maintaining American Superiority by Improving Export Control Transparency Act; Support for anticorruption language in H.R.5300, Department of State Policy Provisions Act.
Client expense: $30,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), Treasury, Dept of, White House Office
2025 · third_quarter · Health Issues
Living Donor Protection Act (H.R. 4583 / S. 1552); FY 2026 appropriations funding for nursing workforce development programs and National Institute of Nursing Research; FY 2026 funding kidney disease research at NIDDK at NIH; Funding for AHRQ at HHS in FY 2026; Workplace Violence Prevention for Health Care and Social Service Workers Act (H.R. 2531 / S. 1232); Restore Protections for Dialysis Patients Act (H.R. 2199 / S. 1173); Organ Donation Referral Improvement Act (H.R. 330); The Improving Care & Access to Nurses Act (H.R. 1316 / S. 575); Providing Real-world Education and Clinical Experience by Precepting Tomorrow's Nurses Act (H.R. 392 / S. 131); Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R.929 / S.266); Living Donor FMLA Protection Act (H.R. 4582); Improving Access to Home Dialysis Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Trade (domestic/foreign)
General issues related to export controls, including H.R. 1316/S. 744, the Maintaining American Superiority by Improving Export Control Transparency Act, and issues related to tariffs and foreign direct investment in the U.S., License Monopoly prevention and related issues.
Client expense: $144,250 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Foreign Relations
Letter urging a more effective, transparent, and inclusive UNCAC Review Mechanism; Letter urging the 47 Member States of the UN Human Rights Council to adopt a bold, forward-looking resolution that addresses the negative impact of corruption on the enjoyment of human rights; Letter urging the Financial Action Task Force to expedite a robust mutual evaluation of the United States; Urging the administration to robustly enforce the Global Magnitsky Human Rights Accountability Act; Urging the Administration to resume, and appropriate future, U.S. foreign assistance for government accountability or transparency programs; Maintaining American Superiority by Improving Export Control Transparency Act (H.R.1316).
Client expense: $50,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), White House Office
2025 · second_quarter · Health Issues
Home dialysis/home therapies issues; Living Donor Protection Act; FY 2026 appropriations funding for nursing workforce development programs and National Institute of Nursing Research; FY 2026 funding kidney disease research at NIDDK at NIH; Funding for AHRQ at HHS in FY 2026; National Nursing Workforce Center Act; Workplace Violence Prevention for Health Care and Social Service Workers Act; Restore Protections for Dialysis Patients Act; Organ Donation Referral Improvement Act; The Improving Care & Access to Nurses Act (H.R. 1316 / S. 575); Providing Real-world Education and Clinical Experience by Precepting Tomorrow's Nurses Act (H.R. 392 / S. 131); Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R.929 / S.266)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Trade (domestic/foreign)
General issues related to export controls, including H.R. 1316/S. 744, the Maintaining American Superiority by Improving Export Control Transparency Act, and issues related to tariffs and foreign direct investment in the U.S.
Client expense: $13,775 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Trade (domestic/foreign)
General issues related to export controls, including H.R. 1316/S. 744, the Maintaining American Superiority by Improving Export Control Transparency Act, and issues related to tariffs and foreign direct investment in the U.S.
Client expense: Not reported · Firm income: $60,000
Government targets: Bureau of Industry and Security (BIS), HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Foreign Relations
Letter enhancing anti-corruption Efforts globally by adopting a more effective, transparent and inclusive UNCAC review mechanism; Letter urging a strong review in the Financial Action Task Force's fifth round of mutual evaluations for the U.S.; Urging the administration to robustly enforce the Global Magnitsky Human Rights Accountability Act; Maintaining American Superiority by Improving Export Control Transparency Act (H.R.1316); Kleptocracy Asset Recovery Rewards Program Act (forthcoming legislation)
Client expense: $30,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), White House Office
2025 · first_quarter · Health Issues
Home dialysis/home therapies issues; Living Donor Protection Act; FY 2026 appropriations funding for nursing workforce development programs and National Institute of Nursing Research; FY 2026 funding kidney disease research at NIDDK at NIH; Funding for AHRQ at HHS in FY 2026; National Nursing Workforce Center Act; Workplace Violence Prevention for Health Care and Social Service Workers Act; Restore Protections for Dialysis Patients Act; Organ Donation Referral Improvement Act; The Improving Care & Access to Nurses Act (H.R. 1316 / S. 575); Providing Real-world Education and Clinical Experience by Precepting Tomorrow's Nurses Act (H.R. 392 / S. 131)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Received in the Senate and Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H1834-1835)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H1834-1835)
DEBATE - The House proceeded with forty minutes of debate on H.R. 1316.
Considered under suspension of the rules. (consideration: CR H1834-1836)
Mr. Mast moved to suspend the rules and pass the bill, as amended.
Referred to the House Committee on Foreign Affairs.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| February 13, 2025 |
| Enrolled Bill | -- |
Client expense: $170,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE